| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imperial Cancer Research Fund Medical Oncology Unit and Medical Research Council Human Genetics Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU [H. G., J. E. V. W., K. T., J. M., R. C. F. L., D. J. P., J. F. S.], and School of Biological and Medical Sciences, University of St. Andrews, St. Andrews, [C. M. S.], United Kingdom
Previous cytogenetic and loss of heterozygosity (LOH) data suggest that disruption of chromosome 11q23-qter occurs frequently in epithelial ovarian cancer and is associated with an adverse clinicopathological phenotype. Ten polymorphic microsatellite repeat loci were analyzed by PCR from the 11q22–q25 region between D11S35 and D11S968 in 40 ovarian tumors (including 31 epithelial ovarian cancers). Two distinct regions of loss were detected, suggesting possible sites for genes involved in epithelial ovarian neoplasia: a large centromeric region between D11S35 and D11S933 (11q22–q23.3) and a telomeric 8.5-Mb region lying between D11S934 and D11S1320 (11q23.3–24.3) not previously defined. LOH of the latter region but not the former one was significantly associated with poor survival, despite all tumors in this study having LOH somewhere on chromosome 11. This analysis provides a starting point for positional cloning.
1 To whom requests for reprints should be addressed.
2 Supported by a grant from the Scottish Hospitals Endowments Research Trust.
Received 12/29/95. Accepted 1/17/96.
This article has been cited by other articles:
|
|
 |
|
  A. D. PANANI, C. ARAVIDIS, Z. KOSMAIDOU, A. RODOLAKIS, and A. ANTSAKLIS Simple Structural Chromosomal Abnormalities in Advanced Stage of Ovarian Cancer In Vivo, May 1, 2009; 23(3): 425 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Jin, A. Chen, D.-S. Hsieh, C.-W. Yao, M.-F. Cheng, and Y.-F. Lin Expression of Serine Protease Matriptase in Renal Cell Carcinoma: Correlation of Tissue Microarray Immunohistochemical Expression Analysis Results with Clinicopathological Parameters International Journal of Surgical Pathology, January 1, 2006; 14(1): 65 - 72. [Abstract] [PDF]
|
|
|
|
 |
|
 C. G. Broustas, P. C. Gokhale, A. Rahman, A. Dritschilo, I. Ahmad, and U. Kasid BRCC2, a Novel BH3-like Domain-containing Protein, Induces Apoptosis in a Caspase-dependent Manner J. Biol. Chem., June 18, 2004; 279(25): 26780 - 26788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Modugno Ovarian Cancer and Polymorphisms in the Androgen and Progesterone Receptor Genes: A HuGE Review Am. J. Epidemiol., February 15, 2004; 159(4): 319 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Stronach, G. C. Sellar, C. Blenkiron, G. J. Rabiasz, K. J. Taylor, E. P. Miller, C. E. Massie, A. Al-Nafussi, J. F. Smyth, D. J. Porteous, et al. Identification of Clinically Relevant Genes on Chromosome 11 in a Functional Model of Ovarian Cancer Tumor Suppression Cancer Res., December 15, 2003; 63(24): 8648 - 8655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Oberst, M. D. Johnson, R. B. Dickson, C.-Y. Lin, B. Singh, M. Stewart, A. Williams, A. al-Nafussi, J. F. Smyth, H. Gabra, et al. Expression of the Serine Protease Matriptase and Its Inhibitor HAI-1 in Epithelial Ovarian Cancer: Correlation with Clinical Outcome and Tumor Clinicopathological Parameters Clin. Cancer Res., April 1, 2002; 8(4): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Sellar, L. Li, K. P. Watt, B. D. Nelkin, G. J. Rabiasz, E. A. Stronach, E. P. Miller, D. J. Porteous, J. F. Smyth, and H. Gabra BARX2 Induces Cadherin 6 Expression and Is a Functional Suppressor of Ovarian Cancer Progression Cancer Res., October 1, 2001; 61(19): 6977 - 6981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Pulido, M. J. Fakruddin, A. Chatterjee, E. D. Esplin, N. Beleño, G. Martínez, H. Posso, G. A. Evans, and V. V. V. S. Murty Identification of a 6-cM Minimal Deletion at 11q23.1-23.2 and Exclusion of PPP2R1B Gene as a Deletion Target in Cervical Cancer Cancer Res., December 1, 2000; 60(23): 6677 - 6682. [Abstract] [Full Text]
|
|
|
|
|
|
M. Duvic, B. Helekar, C. Schulz, M. Cho, D. DiSepio, C. Hager, D. DiMao, P. Hazarika, B. Jackson, J. Breuer-McHam, et al. Expression of a Retinoid-inducible Tumor Suppressor, Tazarotene-inducible Gene-3, Is Decreased in Psoriasis and Skin Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3249 - 3259. [Abstract] [Full Text]
|
|
|
|
|
|
K. C. Connolly, H. Gabra, C. J. Millwater, K. J. Taylor, G. J. Rabiasz, J. E. V. Watson, J. F. Smyth, A. H. Wyllie, and D. I. Jodrell Identification of a Region of Frequent Loss of Heterozygosity at 11q24 in Colorectal Cancer Cancer Res., June 1, 1999; 59(12): 2806 - 2809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-M. Lau, S. C. Mok, and S.-M. Ho Expression of human estrogen receptor-alpha and -beta , progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells PNAS, May 11, 1999; 96(10): 5722 - 5727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Kang, M. Gao, J. L. Feinleib, P. D. Cotter, S. N. Guadagno, and R. S. Krauss CDO: An Oncogene-, Serum-, and Anchorage-regulated Member of the Ig/Fibronectin Type III Repeat Family J. Cell Biol., July 14, 1997; 138(1): 203 - 213. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
